Prosperity Consulting Group LLC Sells 901 Shares of Johnson & Johnson (NYSE:JNJ)

Prosperity Consulting Group LLC lowered its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 5.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,470 shares of the company’s stock after selling 901 shares during the period. Prosperity Consulting Group LLC’s holdings in Johnson & Johnson were worth $2,237,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in JNJ. Aquatic Capital Management LLC grew its position in Johnson & Johnson by 914.7% during the 4th quarter. Aquatic Capital Management LLC now owns 64,938 shares of the company’s stock valued at $9,391,000 after purchasing an additional 58,538 shares during the last quarter. Oxford Asset Management LLP grew its holdings in shares of Johnson & Johnson by 257.8% during the fourth quarter. Oxford Asset Management LLP now owns 12,219 shares of the company’s stock valued at $1,767,000 after buying an additional 8,804 shares during the last quarter. Coldstream Capital Management Inc. increased its position in shares of Johnson & Johnson by 0.5% during the fourth quarter. Coldstream Capital Management Inc. now owns 48,436 shares of the company’s stock valued at $7,005,000 after acquiring an additional 252 shares in the last quarter. Capital Analysts LLC raised its holdings in Johnson & Johnson by 1.4% in the 4th quarter. Capital Analysts LLC now owns 43,027 shares of the company’s stock worth $6,223,000 after acquiring an additional 580 shares during the last quarter. Finally, Cheviot Value Management LLC lifted its position in Johnson & Johnson by 9.8% in the 4th quarter. Cheviot Value Management LLC now owns 155,318 shares of the company’s stock valued at $22,462,000 after acquiring an additional 13,823 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Stock Down 0.3 %

NYSE JNJ opened at $154.54 on Friday. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The company has a market capitalization of $371.83 billion, a P/E ratio of 23.24, a price-to-earnings-growth ratio of 2.56 and a beta of 0.49. The stock’s 50-day moving average price is $159.48 and its 200-day moving average price is $154.84.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping analysts’ consensus estimates of $2.59 by $0.18. The company had revenue of $21.89 billion for the quarter, compared to analysts’ expectations of $21.65 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. On average, equities research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 3.36%. The ex-dividend date of this dividend is Tuesday, May 27th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.24. Johnson & Johnson’s dividend payout ratio is presently 57.84%.

Wall Street Analysts Forecast Growth

JNJ has been the subject of a number of research analyst reports. Wells Fargo & Company reduced their target price on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a report on Thursday, January 23rd. Stifel Nicolaus decreased their target price on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a research report on Thursday, January 23rd. Barclays reduced their price target on shares of Johnson & Johnson from $166.00 to $165.00 and set an “equal weight” rating for the company in a research note on Thursday, April 17th. Bank of America lowered their price objective on shares of Johnson & Johnson from $171.00 to $159.00 and set a “neutral” rating on the stock in a research report on Thursday, April 10th. Finally, Leerink Partners cut their target price on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research report on Thursday, January 23rd. Nine analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus price target of $171.82.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 6,999 shares of the stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the sale, the vice president now directly owns 21,001 shares of the company’s stock, valued at $3,483,645.88. This trade represents a 25.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Timothy Schmid sold 403 shares of the business’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the transaction, the executive vice president now directly owns 15,098 shares in the company, valued at $2,357,552.70. This trade represents a 2.60 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.